AmyPore is a Biotechnology company that designs therapeutic peptides with the aim of developing treatments for neurodegenerative diseases: Alzheimer's disease & Parkinson's disease.
Our main product, AmyP53, is a therapeutic peptide derived from scientific research.
Its design is based on an innovative strategy based on molecular modeling applied to neuroscience. This strategy has made it possible to combine, in a multi-parameter specification: targeting of a fundamental mechanism common to Alzheimer's and Parkinson's diseases, low-dose therapeutic action, absence of side effects at this stage of the research, administration not invasive (nasal spray).
AmyP53 is the first representative of a new therapeutic class capable of treating Alzheimer’s and Parkinson’s diseases.
Understanding the mechanisms responsible for Alzheimer’s and Parkinson’s diseases to lead us to innovative treatments. Develop a new therapeutic class.
AmyPore is a Biotech founded in 2018 on the basis of the scientific discoveries of Pr. Nouara Yahi and Jacques Fantini, researchers in molecular neuroscience at the University of Aix-Marseille.
AmyPore is supported by the European Commission, Kedge Business School and the inter-university incubator IMPULSE.
The company obtained a grant H2020 SME Phase 1.
AmyPore is currently performing the last preclinical tests to launch its first clinical trial in humans as early as 2021